IGC Pharma Balance Sheet Health
Financial Health criteria checks 3/6
IGC Pharma has a total shareholder equity of $7.9M and total debt of $136.0K, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are $10.6M and $2.7M respectively.
Key information
1.7%
Debt to equity ratio
US$136.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.82m |
| Equity | US$7.88m |
| Total liabilities | US$2.71m |
| Total assets | US$10.59m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IGS1's short term assets ($4.4M) exceed its short term liabilities ($2.5M).
Long Term Liabilities: IGS1's short term assets ($4.4M) exceed its long term liabilities ($225.0K).
Debt to Equity History and Analysis
Debt Level: IGS1 has more cash than its total debt.
Reducing Debt: IGS1's debt to equity ratio has increased from 0.2% to 1.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IGS1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IGS1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.5% each year